home / stock / dsnky / dsnky articles
On Wednesday, the FDA issued a Complete Response Letter (CRL) for the Biologics License Application (BLA) seeking accelerated approval of Daiichi S...
On Tuesday, AstraZeneca Plc (NASDAQ:AZN) said the survival results did not reach statistical significance in the overall trial population...
AstraZeneca plc (NASDAQ:AZN) reported topline data from a metastatic breast cancer treatment study. The results showed that Enhertu (t...
Pfizer Inc (NYSE:PFE) is set to announce its fourth quarter 2023 earnings next week on 30th January. The analysts expect the US pharma giant to re...
Esperion Therapeutics, Inc. (NASDAQ: ESPR) shares are trading lower on Wednesday after the company announced a $125 million amendment to the c...
AstraZeneca Plc (NASDAQ: AZN) and Daiichi Sankyo (OTC: DSKYF) (OTC: DSNKY) released topline data from the TROPION-Bre...
Daiichi Sankyo (OTC: DSKYF) (OTC: DSNKY) and AstraZeneca plc (NASDAQ: AZN) released initial results from the TROPION-Lung04 phase 1b...
News, Short Squeeze, Breakout and More Instantly...
Daiichi Sankyo Co Ltd Sponsored ADR Level 1 Company Name:
DSNKY Stock Symbol:
OTCMKTS Market:
Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig PR Newswire Phase 3 trial evaluating rilvegostomig as monotherapy and in combination with AstraZeneca and Daiichi Sankyo's datopotamab deruxtecan in ...
2023-10-31 10:15:00 ET Big pharmas have the resources to make big, multi-year moves that can reshape or even redefine their businesses. As you may know, Merck (NYSE: MRK) is one of the largest of the big pharmas, with a market capitalization of $262 billion, and it just made one of ...
Astellas, Eisai, Daiichi Sankyo and Takeda Agree to Collaborate to Reduce Environmental Burden in the Field of Pharmaceutical Packaging PR Newswire TOKYO and OSAKA, Japan , Dec. 21, 2022 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO:...